CliffBio
small molecule

XOPENEX HFA

LEVALBUTEROL TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameXOPENEX HFA
Active ingredientLEVALBUTEROL TARTRATE
StrengthEQ 0.045MG BASE/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalMarch 2005
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

XOPENEX HFA patent cliff — loss of exclusivity — | CliffBio